Clinical research is changing. As pharmaceutical, biotechnology, and medical device companies develop increasingly sophisticated therapies, ensuring that clinical trials include people who reflect the populations expected to use those products has become an important part of trial planning. Diversity, Equity & Inclusion in Trials (DEI) is not simply about reaching enrollment numbers. It involves identifying participation barriers, understanding patient needs, improving access, and creating clinical research programs that can generate meaningful evidence across diverse populations.

For life sciences organizations, effective Patient Recruitment must therefore go beyond traditional outreach. It requires thoughtful study design, accessible communication, community relationships, and engagement with patient advocacy organizations. At BioNetwork Consulting, clinical trial recruitment is one of the company’s core areas of expertise, supporting pharmaceutical companies, biotech organizations, CROs, CDMOs, and medical device companies throughout the clinical development lifecycle.

Why Diversity Matters in Clinical Trials

Clinical trials are intended to generate evidence about the safety and effectiveness of medical products. If trial participants do not adequately reflect the people who may ultimately use a product, questions can remain about how results apply across different populations.

The FDA’s December 2025 final guidance, “Enhancing Participation in Clinical Trials — Eligibility Criteria, Enrollment Practices, and Trial Designs,” recommends approaches for increasing enrollment of representative populations. The guidance addresses demographic characteristics such as sex, race, ethnicity, age, and location of residence, as well as non-demographic characteristics including disabilities, comorbidities, organ dysfunction, weight ranges, and diseases with low prevalence.

This broader perspective is important because diversity is not represented by a single demographic category. Different patients can experience different barriers to participation, and trial planning should account for the characteristics of the population likely to use the medical product.

Understanding Diversity, Equity & Inclusion in Trials

Diversity focuses on ensuring that clinical research includes participants with a broad range of relevant characteristics.

Equity involves identifying and addressing barriers that may prevent certain populations from having a meaningful opportunity to participate.

Inclusion means creating trial processes that allow eligible participants to participate and remain engaged throughout the study.

Together, these principles can influence protocol development, site selection, recruitment communications, transportation support, language accessibility, participant education, retention strategies, and community outreach.

The FDA has long emphasized the importance of demographic subgroup participation and data quality. Its earlier Section 907 action plan identified three major areas: improving data quality, addressing barriers to subgroup participation, and increasing transparency.

Patient Recruitment Requires More Than Finding Participants

Patient Recruitment is one of the most visible challenges in clinical research, but successful recruitment starts well before a recruitment advertisement is created.

Sponsors and research organizations need to understand where appropriate participants are located, what obstacles may prevent participation, and which communication channels are most trusted by the relevant communities.

A practical recruitment strategy can include:

• Identifying appropriate patient populations early in study planning
• Selecting clinical sites with access to diverse patient communities
• Reviewing eligibility criteria for unnecessary barriers
• Developing clear and culturally appropriate recruitment materials
• Providing information in languages relevant to the target population
• Considering transportation, scheduling, and logistical challenges
• Working with healthcare providers and community organizations
• Monitoring enrollment patterns throughout the study
• Adjusting recruitment strategies when specific populations are not being reached

The FDA’s 2025 guidance specifically discusses eligibility criteria, enrollment practices, and trial designs as areas where sponsors can consider approaches to increase participation.

Patient Advocacy Can Strengthen Clinical Research

Patients bring perspectives that cannot always be obtained from clinical or regulatory teams alone. Patient Advocacy & Community Engagement can help sponsors understand what matters to people living with a disease and how research processes affect their willingness and ability to participate.

Patient advocacy organizations can contribute to clinical development by helping organizations understand patient priorities, communication preferences, practical barriers, and concerns about participating in research.

Engagement can begin before recruitment starts. Sponsors can seek input from patient communities during protocol planning, educational content development, recruitment strategy creation, and study communications.

This approach can make clinical research more patient-centered while helping organizations identify potential barriers earlier in the development process.

The FDA’s patient-focused drug development resources include patient experience information, Patient Listening Sessions, and Patient-Focused Drug Development meetings, reflecting the role of patient perspectives in therapeutic development.

Building Stronger Community Engagement Strategies

Community engagement can be especially valuable when clinical trials need to reach populations that have historically been underrepresented in research.

Instead of relying exclusively on conventional recruitment channels, organizations can build relationships with community-based groups, advocacy organizations, healthcare providers, local organizations, and other trusted networks.

Effective engagement should be based on communication and trust rather than simply promoting a study. Communities should receive understandable information about the purpose of the research, eligibility requirements, study expectations, potential benefits and risks, and participant rights.

Clear communication can also help address misconceptions about clinical research.

The FDA notes that participation in clinical trials is voluntary and that participants should receive information through the informed consent process before agreeing to participate.

Connecting DEI With Clinical Trial Recruitment

DEI should not be treated as a separate activity that begins after a trial struggles to meet enrollment goals. It can be integrated into the clinical development strategy from the beginning.

A more connected approach may involve five stages:

1. Understand the Intended Patient Population

Begin by identifying who is expected to use the medical product and examining the characteristics of that population.

2. Identify Participation Barriers

Review eligibility criteria, trial locations, visit schedules, transportation requirements, language needs, and other practical factors that may influence participation.

3. Build a Targeted Recruitment Strategy

Use multiple recruitment channels and establish relationships with healthcare professionals, advocacy organizations, and community groups that can help reach appropriate participants.

4. Engage Patients and Communities

Create opportunities to listen to patient perspectives and incorporate relevant insights into recruitment and trial communications.

5. Monitor and Adapt

Recruitment should be monitored throughout the study. If particular populations are not being reached as planned, sponsors can evaluate whether recruitment channels, site strategies, communications, or operational processes need adjustment.

Preparing for the Evolving FDA Environment in 2026

Regulatory expectations surrounding clinical trial diversity continue to evolve. FDA’s 2024 draft guidance on Diversity Action Plans described proposed approaches for increasing enrollment of historically underrepresented populations and outlined concepts involving enrollment goals, rationale, and strategies for achieving those goals.

At the same time, FDA’s December 2025 final guidance provides current recommendations on eligibility criteria, enrollment practices, and trial designs for increasing participation in clinical trials.

Organizations planning trials in 2026 should therefore keep their recruitment and development strategies aligned with the latest applicable FDA requirements and guidance rather than relying on older approaches.

Importantly, FDA explains that its clinical trial guidance documents generally represent the agency’s current thinking and recommendations; guidance should not automatically be treated as binding unless a specific statutory or regulatory requirement applies.

How BioNetwork Consulting Supports Clinical Trial Recruitment

BioNetwork Consulting combines life sciences expertise with specialized clinical talent recruitment to help organizations address the operational demands of clinical development.

Its recruitment services support pharmaceutical companies, biotech startups, CROs, CDMOs, and medical device organizations that require qualified professionals across the clinical trial lifecycle. The company’s broader expertise spans pre-clinical development, clinical operations, commercialization, quality, regulatory compliance, and Computer System Validation.

For organizations developing a Patient Recruitment strategy, this combination of industry knowledge and specialized recruitment experience can support a more structured approach to building clinical teams and managing research programs.

BioNetwork Consulting focuses on connecting life sciences organizations with specialized professionals while understanding the regulatory and operational environment in which clinical research takes place.

Moving Toward More Patient-Centered Clinical Research

Diversity, Equity & Inclusion in Trials (DEI) is closely connected with Patient Recruitment and Patient Advocacy & Community Engagement. Each component addresses a different part of the same challenge: creating clinical research that can reach appropriate participants, understand their experiences, and generate evidence that is meaningful for the intended patient population.

For sponsors and life sciences organizations, the goal should be to consider diversity and patient engagement early rather than treating them as last-minute recruitment solutions.

As clinical research continues to evolve in 2026, organizations that combine thoughtful study design, targeted recruitment, patient perspectives, community relationships, and regulatory awareness can create a stronger foundation for clinical development.

BioNetwork Consulting brings together clinical recruitment expertise and life sciences consulting knowledge to help organizations navigate these challenges. By connecting specialized talent with compliance-focused strategies, BioNetwork Consulting supports companies working to move innovative therapies and medical technologies from development toward the patients who need them.